X-Message-Number: 6940 Subject: Visser Method - Clarification Date: Thu, 19 Sep 96 17:33:30 GMT From: (Michelle Olga Visser) Visser method Clarification Due to many requests for additional information about the Visser Method, CPA, Toxicity etc, I feel obliged to CI/Alcor to make the following disclosures:- CI/Alcor agreement : A pre-patent licensing / co-operation agreement was reached between Cryopreservation Technologies cc and CI/Alcor, to apply, research and sublicence the Visser method technology (present and future) with respect to cryonics (only), in exchange for financial assistance (partial funding) of pig heart(cryobiology)and organ re-implantation trials. This is very costly, and my personal resources are not unlimited. The has been no interest on the part of biomedical companies to fund this research without the first scientific publication, and I would not expect them to. CI/Alcor are however bound by secrecy concerning detail of the technology, as are all co-operating labs for reasons explained below, until such time as journal publication of the technology and then disclosure is limited by the detail of paper/s published by myself and or any of my associated co-operating labs. The CPA , - why the secrecy? The CPA is as a grossly under examined, undervalued compound in most respects. In cryogenics and cryobiology there is scope for scores of scientists to examine "unchartered territory" and publish new material. The cryobiological application in itself is thousands of times more commercially viable and than the cryonics application would be (initially) But this technology is also valuable for it's medical application/s which is in turn many times more valuable than that of cryobiology. Given the time limitation of the patent applications (one year), The secrecy aspect should be abundantly clear to everyone. Co-working arrangements:- I have not kept the technology to myself however. Cryobiologists, pathologists, surgeons and physicists who approached me have shared in the technology, forming part of a larger co-operation and information sharing "team", extending the applications of the technology. The door has always been open for those who would expand on the research, as long as they fund their own research and share the detailed information. I am happy to say that research is being conducted on all five continents of the globe, since CI/Alcor have joined the group. Toxicity:- Applied per my method, their is no known toxic effects to date, nor any reason to believe there would be. There is however ongoing research on this aspect. Toxicity clinical trials with humans for use of the compound as a drug are almost completed here in SA, and results will be made available before the end of this year. Why CI/Alcor:? As the founder/father of cryonics, Professor Robert Ettinger was the obvious choice to initiate the cryonics potential of this technology. CI/Alcor representing 70% of cryonicists, would ensure that their members got the earliest benefit of the technology - if it proved useful to them. CI/Alcor will do their research, with or without your donations. When you are asked for contributions, I don't believe this is to enrich any one, but merely a plea to help speed up testing/refining/adapting an available technology. I am not a cryonicist, but whatever the CPA is/is not, I believe it is far better and much faster penetrating CPA than glycerol. The onus now is on CI/Alcor to test and make use of this technology, but to do so without endangering my overall program. Why not wait until publication, then try it yourself? The publication which will probably be published by Nov/Dec is a year old, basic and was the result of one research teams' initial trial on 12 rat hearts. Current technology is one year advanced and the sum of co-operating research teams. Why donate to CI/Alcor now? CI/Alcor have an arrangement and access to all information, past, current and future of our co-operation groups (with respect to cryo). By limiting them now, because of their contractual restraints you might quite well be limiting yourself or a close friend of a "better" preservation. Saul Kent's proposal is welcomed, and will be evaluated for practical and commercial implications. I sincerely hope this posting has placed some issues in a different perspective for at least some of you. Best wishes, Olga ---- Michelle Olga Visser CEO Cryopreservation Technologies cc Phone : +27 12 3541677 (W) +27 12 3310701 (H) E-mail: Rate This Message: http://www.cryonet.org/cgi-bin/rate.cgi?msg=6940